KR20230148418A - 호흡기 바이러스 감염에 대한 보호 항체 - Google Patents

호흡기 바이러스 감염에 대한 보호 항체 Download PDF

Info

Publication number
KR20230148418A
KR20230148418A KR1020237032306A KR20237032306A KR20230148418A KR 20230148418 A KR20230148418 A KR 20230148418A KR 1020237032306 A KR1020237032306 A KR 1020237032306A KR 20237032306 A KR20237032306 A KR 20237032306A KR 20230148418 A KR20230148418 A KR 20230148418A
Authority
KR
South Korea
Prior art keywords
seq
ser
sequence
gly
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237032306A
Other languages
English (en)
Korean (ko)
Inventor
저스틴 제이. 테일러
짐 분야라타나코른키트
Original Assignee
프레드 허친슨 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프레드 허친슨 캔서 센터 filed Critical 프레드 허친슨 캔서 센터
Publication of KR20230148418A publication Critical patent/KR20230148418A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/1027—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
KR1020237032306A 2021-02-26 2022-02-25 호흡기 바이러스 감염에 대한 보호 항체 Pending KR20230148418A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163154166P 2021-02-26 2021-02-26
US63/154,166 2021-02-26
PCT/US2022/017945 WO2022183018A1 (en) 2021-02-26 2022-02-25 Protective antibodies against respiratory viral infections

Publications (1)

Publication Number Publication Date
KR20230148418A true KR20230148418A (ko) 2023-10-24

Family

ID=83048466

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237032306A Pending KR20230148418A (ko) 2021-02-26 2022-02-25 호흡기 바이러스 감염에 대한 보호 항체

Country Status (7)

Country Link
US (1) US20240150444A1 (https=)
EP (1) EP4297780A4 (https=)
JP (1) JP2024507948A (https=)
KR (1) KR20230148418A (https=)
AU (1) AU2022227761A1 (https=)
CA (1) CA3209869A1 (https=)
WO (1) WO2022183018A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
US20250304657A1 (en) * 2022-08-29 2025-10-02 Fred Hutchison Cancer Center Antibodies with novel fc modification combinations that increase antibody function
WO2024077268A2 (en) * 2022-10-07 2024-04-11 Fred Hutchinson Cancer Center Human metapneumovirus antibodies and uses thereof
WO2025165833A1 (en) * 2024-01-29 2025-08-07 Vanderbilt University Hpiv3-neutralizing antibodies and methods of use thereof
CN119039429B (zh) * 2024-08-27 2025-10-03 浙江大学 一种抗RBD单链抗体No.35及制备抗体偶联药物的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2504364T3 (pl) * 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
CN104350069B (zh) * 2012-03-20 2017-12-01 胡默波斯生物医学公司 中和rsv、mpv和pvm的抗体和其应用
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
CN110035771B (zh) * 2016-10-21 2024-03-08 阿迪马布有限责任公司 抗呼吸道合胞病毒抗体及其产生和使用方法
WO2019165019A1 (en) * 2018-02-21 2019-08-29 Vanderbilt University Antibodies to human respiratory syncytial virus protein f pre-fusion conformation and methods of use therefor
US11066469B2 (en) * 2019-06-12 2021-07-20 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use

Also Published As

Publication number Publication date
JP2024507948A (ja) 2024-02-21
WO2022183018A1 (en) 2022-09-01
CA3209869A1 (en) 2022-09-01
US20240150444A1 (en) 2024-05-09
AU2022227761A9 (en) 2024-01-25
EP4297780A1 (en) 2024-01-03
EP4297780A4 (en) 2025-07-16
AU2022227761A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
TWI859420B (zh) 抗sars-cov-2抗體及使用其之方法
KR102535195B1 (ko) 항-코로나바이러스 항체 및 사용 방법
KR20230148418A (ko) 호흡기 바이러스 감염에 대한 보호 항체
TWI896628B (zh) 針對嚴重急性呼吸症候群冠狀病毒２(SARS-CoV-2)之人單株抗體
CN104169298B (zh) 可结合并中和b型流感病毒的人类结合分子及其用途
ES2541142T3 (es) Composiciones y métodos para anticuerpos dirigidos contra la proteína C5 del complemento
US20230331824A1 (en) Single-domain antibodies that bind sars-cov-2
CN112625136A (zh) 针对冠状病毒具有中和活性的双特异性抗体及其用途
CA3175533A1 (en) Antibodies against sars-cov-2 and methods of using the same
JP2023528826A (ja) Ｓａｒｓ関連コロナウイルスに対する中和抗体
JP2020532285A (ja) 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
US20250188154A1 (en) Coronavirus antibodies and uses thereof
EP4330278A1 (en) Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
WO2021247925A1 (en) Structure-guided immunotherapy against sars-cov-2
AU2012245073B2 (en) Modified variable domain molecules and methods for producing and using them b
EP4230650A1 (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
TW202144406A (zh) ＳＡＲＳ－ＣｏＶ－２抗體及其應用
WO2022060838A1 (en) Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same
RU2782256C2 (ru) Антитела к коронавирусу и способы применения
WO2024211789A1 (en) Cross-flavivirus binding domains and uses thereof
CN117836322A (zh) 针对SARS-CoV-2的人中和单克隆抗体及其用途
WO2024068996A1 (en) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
CN117337301A (zh) 抗体
CN116406375A (zh) 抗SARS-CoV-2刺突蛋白的三聚体抗体
WO2024036313A9 (en) Anti-sars-cov-2 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000